HomeInsightsStock Comparison

Concord Biotech Ltd vs Concord Drugs Ltd Stock Comparison

Concord Biotech Ltd vs Concord Drugs Ltd Stock Comparison

Last Updated on: Aug 02, 2025

Key Highlights

  • The Latest Trading Price of Concord Biotech Ltd is ₹ 1739 as of 01 Aug 15:30.
  • The P/E Ratio of Concord Biotech Ltd changed from 51.7 on March 2024 to 0 on March 2021 . This represents a CAGR of -100.00% over 3 yearsThe P/E Ratio of Concord Drugs Ltd changed from 15.9 on March 2022 to 0 on March 2021 . This represents a CAGR of -100.00% over 5 years.
  • The Market Cap of Concord Biotech Ltd changed from ₹ 15922 crore on March 2024 to ₹ 0 crore on March 2021 . This represents a CAGR of -100.00% over 3 yearsThe Market Cap of Concord Drugs Ltd changed from ₹ 25.36 crore on March 2022 to ₹ 0 crore on March 2021 . This represents a CAGR of -100.00% over 5 years.
  • The revenue of Concord Biotech Ltd for the Mar '25 is ₹ 439.27 crore as compare to the Dec '24 revenue of ₹ 260.78 crore. This represent the growth of 68.44% The revenue of Concord Drugs Ltd for the Mar '25 is ₹ 10.4 crore as compare to the Dec '24 revenue of ₹ 10.8 crore. This represent the decline of -3.7%.
  • The ebitda of Concord Biotech Ltd for the Mar '25 is ₹ 198.26 crore as compare to the Dec '24 ebitda of ₹ 114.51 crore. This represent the growth of 73.14% The ebitda of Concord Drugs Ltd for the Mar '25 is ₹ 1.05 crore as compare to the Dec '24 ebitda of ₹ 1.39 crore. This represent the decline of -24.46%.
  • The net profit of Concord Biotech Ltd changed from ₹ 54.49 crore to ₹ 140.39 crore over 8 quarters. This represents a CAGR of 60.51% The net profit of Concord Drugs Ltd changed from ₹ 0.49 crore to ₹ 0.04 crore over 8 quarters. This represents a CAGR of -71.43% .
  • The Dividend Payout of Concord Biotech Ltd changed from 24.05 % on March 2020 to 30.03 % on March 2024 . This represents a CAGR of 4.54% over 5 yearsThe Dividend Payout of Concord Drugs Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Concord Biotech Ltd

  • Concord Biotech Limited was originally incorporated as Servomed Pharmaceuticals Private Limited' at Ahmedabad, Gujarat as a Private Limited Company dated November 23, 1984, issued by the Registrar of Companies.
  • Thereafter, name of the Company was changed to Concord Biotech Limited' dated February 16, 2001, which became a Public Company and a fresh Certificate of Incorporation dated November 7, 2001 was issued by the RoC. The Company is an India-based bio pharma and one of the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology in terms of market share, based on volume in supplying to over 70 countries including regulated markets, such as the United States, Europe and Japan, and India.
  • Presently, it is engaged in research and development, manufacturing, marketing and selling of pharmaceutical products.

About Concord Drugs Ltd

  • Concord Drugs Limited, established in 1995, is amongst the respected pharmaceutical companies in India for manufacturing of Finished Pharmaceutical Formulations like Injectables (Small Volume parenterals, Dry Syrup powder) ,Tissue Bio-Adhesive, tablets, capsules and ophthalmic preparations and Ready-to-fill Pellets. The principal activity of the Company is to manufacture licensed drugs based on the formulations approved.
  • The Company has two manufacturing facilities license issued by The Government of Andhra Pradesh, Drugs Control Administration, and Hyderabad.
  • State of the art technology having dedicated manufacturing facilities for Liquid Injections, Dry powder Injections and Ready-to-fill Pellets ensures the highest level of process integrity and product quality. The Company started with Finished Pharmaceutical Formulations and then diversified into Ready-to-fill Pellets, to provide customers with end-to-end solution to their various pharmaceutical product needs to commercial contract drug manufacturing.

Concord Biotech Ltd News Hub

News

Concord Biotech's Dholka unit clears Russian GMP inspection

Concord Biotech announced the successful completion of the Russian GMP (Good Manufacturing...

Read more

26 Jul 2025 10:02

News

Concord Biotech acquires 75% stake in Stellon Biotech

Concord Biotech has made an equity investment of USD 1,500 in Stellon Biotech Inc. This in...

Read more

02 Jul 2025 12:10

News

Concord Biotech edges higher on value buying; trades above 100-day SMA

The scrip had declined 15.63% in seven sessions to end at Rs 1,780.75 yesterday, from its ...

Read more

25 Jun 2025 11:40

News

Concord Biotech's API facility completes USFDA inspection

Concord Biotech has received an Establishment Inspection Report (EIR) from the US Food and...

Read more

24 Jun 2025 19:06

News

Board of Concord Biotech recommends final dividend

Concord Biotech announced that the Board of Directors of the Company at its meeting held o...

Read more

30 May 2025 11:14

News

Concord Biotech to announce Quarterly Result

Concord Biotech will hold a meeting of the Board of Directors of the Company on 29 May 202...

Read more

24 May 2025 18:40

Concord Drugs Ltd News Hub

News

Concord Drugs announces board meeting date

Concord Drugs will hold a meeting of the Board of Directors of the Company on 8 August 202...

Read more

02 Aug 2025 12:51

News

Concord Drugs EGM scheduled

Concord Drugs announced that an Extra Ordinary General Meeting (EGM) of the Company will b...

Read more

10 Jul 2025 17:51

News

Concord Drugs to hold EGM

Concord Drugs announced that an Extra Ordinary General Meeting (EGM) of the Company will b...

Read more

04 Jul 2025 16:31

News

Concord Drugs to hold board meeting

Concord Drugs will hold a meeting of the Board of Directors of the Company on 3 July 2025....

Read more

01 Jul 2025 14:20

News

Concord Drugs to hold board meeting

Concord Drugs will hold a meeting of the Board of Directors of the Company on 27 June 2025...

Read more

20 Jun 2025 10:07

News

Concord Drugs to announce Quarterly Result

Concord Drugs will hold a meeting of the Board of Directors of the Company on 23 May 2025....

Read more

17 May 2025 15:21

SWOT Analysis Of Concord Biotech Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Concord Biotech Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Concord Drugs Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Concord Biotech Ltd and Concord Drugs Ltd

Which company has a larger market capitalization, Concord Biotech Ltd or Concord Drugs Ltd?

Market cap of Concord Biotech Ltd is 18,200 Cr while Market cap of Concord Drugs Ltd is 56 Cr

What are the key factors driving the stock performance of Concord Biotech Ltd and Concord Drugs Ltd?

The stock performance of Concord Biotech Ltd and Concord Drugs Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Concord Biotech Ltd and Concord Drugs Ltd?

As of August 2, 2025, the Concord Biotech Ltd stock price is INR ₹1739.7. On the other hand, Concord Drugs Ltd stock price is INR ₹56.0.

How do dividend payouts of Concord Biotech Ltd and Concord Drugs Ltd compare?

To compare the dividend payouts of Concord Biotech Ltd and Concord Drugs Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions